BioLineRx (BLRX) News
NASDAQ: BLRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.9639-0.0861 (-8.20%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BLRX news summary
We found 2 recent headlines mentioning BioLineRx (BLRX): 1 in the past week and 1 in the past 30 days, most often from Nasdaq. BLRX is making an outsized move today, down 8.20% at $0.9639, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "BioLineRx Ltd. and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates at SNO 2026", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BioLineRx headlines
- BioLineRx Ltd. and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates at SNO 2026BioLineRx Ltd. and Hemispherian AS announced the presentation of Phase 1/2a clinical study and pre-clinical updates for GLIX1 at the 31st Society for Neuro-Oncology (SNO) Annual Meeting. GLIX1 is a…Nasdaq
- BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026BioLineRx Ltd. and Hemispherian AS announced they presented preclinical data at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026) demonstrating synergy between GLIX1 and…NasdaqBLRX, LEN.B